Company news

aTyr Pharma, Inc. news in 2026

aTyr Pharma, Inc.'s news releases, calls and decks from 2026, newest first.

View company

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

October 29, 2026

aTyr Pharma Announces One-for-40 Reverse Stock Split

October 27, 2026

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

October 19, 2026

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

October 13, 2026

ATyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

September 24, 2026

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

September 1, 2026

ATyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

August 10, 2026

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

July 15, 2026

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

May 14, 2026

aTyr Pharma to Participate in Upcoming Investor Conferences

May 13, 2026

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

May 11, 2026

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

March 4, 2026

ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 20, 2026

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

February 3, 2026

Decks in 2026